Show simple item record

dc.contributor.authorSerio, Bianca
dc.contributor.authorPezzullo, Luca
dc.contributor.authorFontana, Raffaele
dc.contributor.authorAnnunziata, Silvana
dc.contributor.authorRosamilio, Rosa
dc.contributor.authorSessa, M.
dc.contributor.authorGiudice, Valentina
dc.contributor.authorFerrara, Ida Lucia
dc.contributor.authorRocco, Monia
dc.contributor.authorDe Rosa, Gennaro
dc.contributor.authorRicci, P.
dc.contributor.authorTauchmanovà, Libuse
dc.contributor.authorMontuori, Nunzia
dc.contributor.authorSelleri, Carmine
dc.date.accessioned2013-05-30T09:43:12Z
dc.date.available2013-05-30T09:43:12Z
dc.date.issued2013
dc.identifier.citationSerio B, Pezzullo L, Fontana R, et al. Accelerated bone mass senescence after hematopoietic stem cell transplantation. Translational Medicine @ UniSa 2013;5(4):7-13en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/650
dc.description.abstractOsteoporosis and avascular necrosis (AVN) are long-lasting and debilitating complications of hematopoietic stem cell transplantation (HSCT). We describe the magnitude of bone loss, AVN and impairment in osteogenic cell compartment following autologous (auto) and allogeneic (allo) HSCT, through the retrospective bone damage revaluation of 100 (50 auto- and 50 allo-HSCT) longterm survivors up to 15 years after transplant. Current treatment options for the management of these complications are also outlined. We found that auto- and allo-HSCT recipients show accelerated bone mineral loss and microarchitectural deterioration during the first years after transplant. Bone mass density (BMD) at the lumbar spine, but not at the femur neck, may improve in some patients after HSCT, suggesting more prolonged bone damage in cortical bone. Phalangeal BMD values remained low for even more years, suggesting persistent bone micro-architectural alterations after transplant. The incidence of AVN was higher in allo-HSCT recipients compared to autoHSCT recipients. Steroid treatment length, but not its cumulative dose was associated with a higher incidence of bone loss. Allo-HSCT recipients affected by chronic graft versus host disease seem to be at greater risk of continuous bone loss and AVN development. Reduced BMD and higher incidence of AVN was partly related to a reduced regenerating capacity of the normal marrow osteogenic cell compartment. Our results suggest that all patients after autoHSCT and allo-HSCT should be evaluated for their bone status and treated with anti-resorptive therapy as soonas abnormalities are detected.en_US
dc.format.extentP. 7-13en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectOsteoporosisen_US
dc.subjectHemopoietic stem cell transplantationen_US
dc.subjectBisphosphonatesen_US
dc.titleAccelerated bone mass senescence after hematopoietic stem cell transplantationen_US
dc.typeArticleen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record